TY - JOUR
T1 - Mantle cell lymphoma
T2 - Non-myeloablative versus dose-intensive therapy
AU - Hagemeister, Frederick B.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2003
Y1 - 2003
N2 - Mantle cell lymphoma. (MCL) is now recognized as an aggressive lymphoma, in which there is frequent development of resistance to chemotherapy and a median survival period of 3-4 years. In recent years, the use of the chimeric monoclonal antibody rituximab, which is directed against the CD20 antigen, has provided new possibilities for the treatment of MCL. Rituximab alone produces overall response rates of 30-33% in patients with MCL, and is also effective at inducing complete responses in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Furthermore, the addition of rituximab to the regimen of fractionated Hyper-CVAD/MTX-AraC (cyclophosphamide/doxorubicin/vincristine/dexamethasone alternated with methotrexate/cytarabine) has been found to produce responses and relapse-free and overall survival in younger patients that are comparable to those seen with Hyper-CVAD/MTX-AraC plus stem cell transplantation. Despite these promising results, patients aged > 65 years have a poor prognosis, and further studies are required to improve outcomes in this population.
AB - Mantle cell lymphoma. (MCL) is now recognized as an aggressive lymphoma, in which there is frequent development of resistance to chemotherapy and a median survival period of 3-4 years. In recent years, the use of the chimeric monoclonal antibody rituximab, which is directed against the CD20 antigen, has provided new possibilities for the treatment of MCL. Rituximab alone produces overall response rates of 30-33% in patients with MCL, and is also effective at inducing complete responses in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Furthermore, the addition of rituximab to the regimen of fractionated Hyper-CVAD/MTX-AraC (cyclophosphamide/doxorubicin/vincristine/dexamethasone alternated with methotrexate/cytarabine) has been found to produce responses and relapse-free and overall survival in younger patients that are comparable to those seen with Hyper-CVAD/MTX-AraC plus stem cell transplantation. Despite these promising results, patients aged > 65 years have a poor prognosis, and further studies are required to improve outcomes in this population.
KW - CHOP stem cell transplantation
KW - Hyper-CVAD/MTX-AraC stem cell transplantation
KW - Mantle cell lymphoma
KW - Rituximab chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=1042280334&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1042280334&partnerID=8YFLogxK
U2 - 10.1080/10428190310001623720
DO - 10.1080/10428190310001623720
M3 - Article
C2 - 15202528
AN - SCOPUS:1042280334
SN - 1042-8194
VL - 44
SP - S69-S75
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - SUPPL. 3
ER -